Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer

LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor

(2013) Y Wang et al.   BRITISH JOURNAL OF CANCER

The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status

(2013) Mikael Johansson et al.   NEURO-ONCOLOGY

LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling

(2013) J J-C Sheu et al.   ONCOGENE

Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival

(2013) Anders Näsman et al.   Cancer Medicine

The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor Suppressor

(2012) Anne E. Powell et al.   CELL

Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity

(2011) Xuping Wu et al.   ACTA ONCOLOGICA

Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ER -Positive Breast Cancer

(2011) S. R. Krig et al.   MOLECULAR CANCER RESEARCH

LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix

(2010) Håkan Hedman et al.   ACTA ONCOLOGICA

Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1

(2010) Wei Yi et al.   EXPERIMENTAL CELL RESEARCH

Human papillomavirus and survival in patients with base of tongue cancer

(2010) Per Attner et al.   INTERNATIONAL JOURNAL OF CANCER

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer

(2010) Marcus Thomasson et al.   INTERNATIONAL JOURNAL OF CANCER

Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma?

(2009) Anders Näsman et al.   INTERNATIONAL JOURNAL OF CANCER

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

(2009) Jean-Pierre Pignon et al.   RADIOTHERAPY AND ONCOLOGY

Lrig1 Is an Endogenous Inhibitor of Ret Receptor Tyrosine Kinase Activation, Downstream Signaling, and Biological Responses to GDNF

(2008) F. Ledda et al.   JOURNAL OF NEUROSCIENCE

LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII

(2008) M A Stutz et al.   ONCOGENE

LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking

(2007) A.K. LINDSTRÖM et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Redistribution of LRIG Proteins in Psoriasis

(2007) Terese Karlsson et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY